Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Standard Concentration of Morphine as a Positive Control for Intradermal Skin Test

This study has been completed.
Sponsor:
Information provided by:
Chulalongkorn University
ClinicalTrials.gov Identifier:
NCT00853476
First received: February 27, 2009
Last updated: February 16, 2011
Last verified: February 2011

February 27, 2009
February 16, 2011
March 2009
October 2009   (final data collection date for primary outcome measure)
Wheal diameter from morphine skin test at different concentrations compared to standard histamine between 15-30 minutes after skin test [ Time Frame: 30 minutes ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00853476 on ClinicalTrials.gov Archive Site
Side effects [ Time Frame: 24 hours ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
The Standard Concentration of Morphine as a Positive Control for Intradermal Skin Test
The Standard Concentration of Morphine as a Positive Control for Intradermal Skin Test

This study aims to compare skin reactivity results between morphine and histamine as a positive control agents in intradermal skin test.

Histamine hydrochloride and different concentrations of morphine sulfate will be intradermally injected and wheal diameter size will be comparatively measured between 15-30 minutes' time points after the test.

Observational
Observational Model: Cohort
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample

Adult Healthy Volunteers

Intradermal Test
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
25
October 2009
October 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • age 18-60 years old

Exclusion Criteria:

  • immunodeficiency state
  • cancer
  • severe skin diseases
  • severe medical illnesses
  • malnutrition
  • uncontrolled asthma
  • pregnancy
  • received oral or systemic corticosteroid within 1 month before this study
  • receiving immunosuppressive agents
  • taken antihistamine within 3 days before this study
  • taking beta-blocker
  • previous history of immunotherapy
  • have hypersensitivity reaction to morphine/opiates
Both
18 Years to 60 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Thailand
 
NCT00853476
Chula-ARC 001/09
No
Jettanong Klaewsongkram, MD, Chulalongkorn University
Chulalongkorn University
Not Provided
Principal Investigator: Jettanong Klaewsongkram, MD Chulalongkorn University
Chulalongkorn University
February 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP